Evidence map›Paper›PMID 33748943›Full record

ArticleBritish journal of haematology2021

Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy.

Chutima Kunacheewa, Lei Feng, Elisabet E Manasanch, Qaiser Bashir, Krina K Patel, Rohtesh Mehta, Gregory P Kaufman, Samer Srour, Neeraj Saini, Swaminathan P Iyer and 5 more

Open access · greenAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Chutima KunacheewaDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lei FengDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Elisabet E ManasanchDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Qaiser BashirDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-4086-6453
Krina K PatelDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rohtesh MehtaDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-8532-544X
Gregory P KaufmanDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Samer SrourDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-6693-2025
Neeraj SainiDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Swaminathan P IyerDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sheeba K ThomasDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Donna M WeberDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Robert Z OrlowskiDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-5723-4129
Muzaffar H QazilbashDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hans C LeeDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-8545-3292
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Proteasome Assembly Chaperones in Sensitivity and Resistance to Proteasome InhibitorsR01CA194264 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ORLOWSKI, ROBERT ZYGMUNT · 2016 to 2020
$1.8M
Role of TJP1 in Sensitivity and Resistance to Proteasome Inhibitors in MyelomaR01CA184464 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ORLOWSKI, ROBERT ZYGMUNT · 2015 to 2019
$1.8M
NCI NIH HHS CA194264NCI NIH HHS P30 CA016672NCI NIH HHS R01s CA184464
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hematopoietic Stem Cell TransplantationMaintenance ChemotherapyAutograftsFemaleFollow-Up StudiesHumansLenalidomideMaleMiddle AgedMultiple MyelomaLenalidomide

Identifiers

PMID33748943
PMCPMC12994767
OpenAlexW3138302233

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.